ong term impact of renin angiotensin system RAS inhibition on cardiorenal outcomes. A randomized controlled trial of cardio-renal effects of RAS inhibition in patients with cardio-renal risk. A comparative trial of Angiotensin Converting Enzyme ACE inhibitors, angiotensin receptor blockers or combined therapy with both agents in patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic. - LIRICO Long term Impact of Renin angiotensin system RAS Inhibition on Cardiorenal Outcomes

CONSORZIO MARIO NEGRI SUD0 个研究点目标入组 2,100 人开始时间: 2007年4月6日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Signing and informed consent Presence of micro/macroalbuminuria already known or detected by measurement of albumin creatinine ration on a morning urine spot in 2 separate occasion, after excluding coexisting causes of increased urine albumin excretion by patient interview and urinary dipstick One or more cardiovascular risk factors Cigarette smoking; Type 1 or 2 diabetes; Hypertension; Visceral obesity; Hypercholesterolemia; Family history of cardiovascular disease. Individuals who have previously presented a major cardio-cerebrovascular event coronary heart disease, non fatal stroke, hospitalization for any cardiovascular cause may be enrolled in the trial provided this event has occurred at least 6 months before enrolment.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Pregnant women Women who intend to become pregnant throughout the 4 years from enrolment to end of study Neoplasia within up to 5 years from assessment of eligibility for study excluding skin cell basalioma Clinically significant aortic obstruction Clear contraindications to use of RAS inhibitors Any condition which significantly reduces life expectancy Non compliant patient .

发起方

CONSORZIO MARIO NEGRI SUD